These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 19522059)
1. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Lyrdal D; Boijsen M; Suurküla M; Lundstam S; Stierner U Nucl Med Commun; 2009 Jul; 30(7):519-24. PubMed ID: 19522059 [TBL] [Abstract][Full Text] [Related]
2. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. Ueno D; Yao M; Tateishi U; Minamimoto R; Makiyama K; Hayashi N; Sano F; Murakami T; Kishida T; Miura T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Inoue T; Kubota Y; Nakaigawa N BMC Cancer; 2012 May; 12():162. PubMed ID: 22551397 [TBL] [Abstract][Full Text] [Related]
3. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Khandani AH; Cowey CL; Moore DT; Gohil H; Rathmell WK Nucl Med Commun; 2012 Sep; 33(9):967-73. PubMed ID: 22714005 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288 [TBL] [Abstract][Full Text] [Related]
5. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated Kelly-Morland C; Rudman S; Nathan P; Mallett S; Montana G; Cook G; Goh V BMC Cancer; 2017 Jun; 17(1):392. PubMed ID: 28578690 [TBL] [Abstract][Full Text] [Related]
11. 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. Ambrosini V; Quarta C; Zinzani PL; Nanni C; Fini M; Torricelli P; Giavaresi G; D'Errico-Grigioni A; Malvi D; Franchi R; Fanti S Q J Nucl Med Mol Imaging; 2010 Dec; 54(6):689-97. PubMed ID: 20639808 [TBL] [Abstract][Full Text] [Related]
12. The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. Kakizoe M; Yao M; Tateishi U; Minamimoto R; Ueno D; Namura K; Makiyama K; Hayashi N; Sano F; Kishida T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Taguri M; Morita S; Inoue T; Kubota Y; Nakaigawa N BMC Cancer; 2014 Jun; 14():390. PubMed ID: 24885730 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Minamimoto R; Nakaigawa N; Tateishi U; Suzuki A; Shizukuishi K; Kishida T; Miura T; Makiyama K; Yao M; Kubota Y; Inoue T Clin Nucl Med; 2010 Dec; 35(12):918-23. PubMed ID: 21206220 [TBL] [Abstract][Full Text] [Related]
14. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750 [TBL] [Abstract][Full Text] [Related]
15. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. Smith AD; Lieber ML; Shah SN AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913 [TBL] [Abstract][Full Text] [Related]
17. Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy. Martínez-Rodríguez I; Banzo I; Carril JM Endocrine; 2013 Aug; 44(1):264-5. PubMed ID: 23564596 [TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
19. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. Lalami Y; Garcia C; Flamen P; Ameye L; Paesmans M; Awada A Head Neck; 2016 Mar; 38(3):347-54. PubMed ID: 25332069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]